scPharmaceuticals Inc (SCPH)
4.895
+0.16
(+3.49%)
USD |
NASDAQ |
May 07, 16:00
4.895
0.00 (0.00%)
After-Hours: 20:00
scPharmaceuticals Enterprise Value: 139.28M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 139.28M |
| May 06, 2024 | 133.34M |
| May 03, 2024 | 130.81M |
| May 02, 2024 | 130.81M |
| May 01, 2024 | 126.48M |
| April 30, 2024 | 123.96M |
| April 29, 2024 | 127.93M |
| April 26, 2024 | 124.68M |
| April 25, 2024 | 119.63M |
| April 24, 2024 | 125.04M |
| April 23, 2024 | 129.01M |
| April 22, 2024 | 127.57M |
| April 19, 2024 | 127.21M |
| April 18, 2024 | 125.40M |
| April 17, 2024 | 122.16M |
| April 16, 2024 | 131.17M |
| April 15, 2024 | 138.02M |
| April 12, 2024 | 140.55M |
| April 11, 2024 | 146.68M |
| April 10, 2024 | 135.14M |
| April 09, 2024 | 143.79M |
| April 08, 2024 | 140.55M |
| April 05, 2024 | 144.15M |
| April 04, 2024 | 148.12M |
| April 03, 2024 | 150.64M |
| Date | Value |
|---|---|
| April 02, 2024 | 135.14M |
| April 01, 2024 | 137.66M |
| March 28, 2024 | 143.79M |
| March 27, 2024 | 144.15M |
| March 26, 2024 | 139.83M |
| March 25, 2024 | 138.02M |
| March 22, 2024 | 149.20M |
| March 21, 2024 | 156.77M |
| March 20, 2024 | 163.98M |
| March 19, 2024 | 156.41M |
| March 18, 2024 | 160.74M |
| March 15, 2024 | 173.00M |
| March 14, 2024 | 153.89M |
| March 13, 2024 | 158.93M |
| March 12, 2024 | 156.05M |
| March 11, 2024 | 153.17M |
| March 08, 2024 | 156.77M |
| March 07, 2024 | 167.23M |
| March 06, 2024 | 175.52M |
| March 05, 2024 | 174.08M |
| March 04, 2024 | 179.12M |
| March 01, 2024 | 183.45M |
| February 29, 2024 | 179.85M |
| February 28, 2024 | 179.33M |
| February 27, 2024 | 186.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.25M
Minimum
Jun 24 2019
341.11M
Maximum
May 12 2023
118.08M
Average
109.12M
Median
Mar 25 2022
Enterprise Value Benchmarks
| Anika Therapeutics Inc | 347.97M |
| Spero Therapeutics Inc | 14.10M |
| electroCore Inc | 31.69M |
| NovaBay Pharmaceuticals Inc | 2.560M |
| Palatin Technologies Inc | 24.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.81M |
| Revenue (Quarterly) | 6.096M |
| Total Expenses (Quarterly) | 21.35M |
| EPS Diluted (Quarterly) | -0.35 |
| Gross Profit Margin (Quarterly) | 70.92% |
| Profit Margin (Quarterly) | -226.6% |
| Earnings Yield | -29.01% |
| Normalized Earnings Yield | -29.01 |